Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
hsa-miR-217
Specific or universal ncRNAs
Specific ncRNAs
Class
MicroRNA
Biomarker
No
Biomarker application
Upstream regulatory factors
Not available
Downstream target
KRAS
Cancer name
Lung Cancer
Cancer site
Lung
Treatment type
Chemotherapy
Drug
Cisplatin
Impact of wild-type ncRNA on chemotherapy resistance
Down
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
MiR-217 suppresses tumour development in lung cancer by targeting KRAS and enhances cell sensitivity to cisplatin.
Tissue resource
pairs of matched lung cancer and noncancerous tissue samples
lung cancer cell lines SPC-A-1
lung cancer cell lines A549
Experiment
qRT-PCR,Western blot,Luciferase reporter assay
Institute
the Cancer Institute and Hospital of Hebei
Country
China
Continent
Asia
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.